Marco Rubio Seeks Gulf Support for U.S.-Iran Peace Deal Amid Regional Concerns 
UNAIDS Urges U.S. to Reconsider South Africa HIV Funding Withdrawal 
US Reaffirms Taiwan Arms Sales Policy Despite Trump’s Comments on China 
CDC Monitors 41 Americans After Andes Hantavirus Outbreak on Luxury Cruise Ship 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
Trump Reportedly Approves Plan to Remove FDA Commissioner Marty Makary Amid Growing Controversies 
Trump Requests $11 Billion More in Farm Aid as Rising Costs Pressure U.S. Farmers 
RFK Jr. Faces Scrutiny Over David Geier’s HHS Role and Vaccine Review Work 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak 
U.S. Reviewing Potential F-35 Fighter Jet Sale to Turkey Amid S-400 Dispute 
Japan Signals Preference for Low Interest Rates as BOJ Policy Debate Intensifies 
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
US Seeks Gulf Support for Iran Peace Deal Amid Regional Tensions 
White House Seeks $87.6 Billion Emergency Funding for Iran War, Farmers, and Ebola Response 
Peru Election Dispute Deepens as Roberto Sanchez Rejects Runoff Results 
A panel of independent U.S. vaccine experts has announced plans to review the long-standing recommendation for administering the hepatitis B vaccine at birth. The Vaccine Integrity Project, an organization focused on ensuring vaccine safety and efficacy, said it expects to complete its review by early December. The move follows a decision by a federal advisory committee under the Centers for Disease Control and Prevention (CDC) to delay a vote on whether to postpone the first hepatitis B dose for newborns of mothers who test negative for the virus.
The review will analyze decades of scientific research on the safety, effectiveness, and public health outcomes of administering the hepatitis B vaccine within the first 24 hours of life. It will also evaluate the potential risks of delaying the vaccine, including missed opportunities for immunization due to incomplete maternal screening or lack of follow-up.
Currently, the CDC and World Health Organization recommend that all newborns receive the hepatitis B vaccine shortly after birth to prevent mother-to-child transmission. Data show that infants infected at birth or within their first year face up to a 90% chance of developing chronic hepatitis B, which can lead to cirrhosis or liver cancer later in life.
The discussion has gained political attention after President Donald Trump questioned the necessity of giving the vaccine at birth, suggesting instead that it could be delayed until age 12, citing its transmission through sexual contact. However, health experts emphasize that perinatal infection remains a significant transmission route.
Since the introduction of widespread vaccination, hepatitis B infection rates in the United States have dropped by nearly 90%, from about 9.6 per 100,000 people before the vaccine program began to around one per 100,000 in 2018. Currently, six hepatitis vaccines are approved for use in the U.S., continuing to play a vital role in reducing the disease’s prevalence and protecting future generations.
